I am a healthcare professional

Notice


Welcome to MEDICALLY. This website is a non-promotional international resource intended to facilitate transparent scientific exchange regarding developments in medical research and disease management. It is intended for healthcare professionals outside the United Kingdom (UK) and Australia. The content on this website may include scientific information about experimental or investigational compounds, indications and services that are not approved or valid in your jurisdiction. Registration status and prescribing information of medicinal products may differ between countries. Roche and Genentech do not support, endorse or recommend the unapproved use of any compound or service in your jurisdiction, including those discussed on this website.


Please refer to local product information for any medicinal products mentioned. Information available on this website does not constitute professional medical advice, and Roche and Genentech accept no responsibility for access to or use of the same. Healthcare professionals outside the US are required to register and log-in to access the full range of content available on this website.


By clicking on one of the healthcare professional buttons below, you acknowledge you have read and understood this message and that you are requesting access to MEDICALLY. If you are not a healthcare professional, please use the other links below to access information relevant to you.


Cookies


We use cookies on this site to enable the site to function properly and to enhance your user experience. Cookies are files stored in your browser, which most websites use to personalize your web experience. Your information will only be used to provide information that is relevant to you. It will not be used for any other purpose. If you wish to restrict or block cookies, which are set on your device, then you can do this through your browser settings.


You can find out more about cookies by browsing our Privacy Policy.

 

I am a healthcare professional
(outside the UK) and Australia:

Not a healthcare professional? For individuals outside the US, browse Roche's patient website or roche.com. For individuals in the US, browse gene.com.

External site

By following this link, you are leaving Medically and entering a website that is not owned or controlled by Roche. Roche does not take any responsibility for access to or use of this website, nor for any content therein.

Leave site
Roche and Genentech at

ESMO 2022

-
Coming soon
10:15 AM
Duration 10mins 4.B – Brest Auditorium
IMmotion010: efficacy and safety from the Phase III study of atezolizumab vs placebo as adjuvant therapy in patients with renal cell carcinoma at increased risk of recurrence following resection
Bex A, Uzzo R, Karam JA, Master V, Donskov F, Suarez C, Albiges L, Rini B, Tomita Y, Kann A, Procopio G, Massari F, Zibelman M, Antonyan I, Huseni M, Basu D, Ci B, Leung W, Khan O, Pal S

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar
11:00 AM
Duration 10mins 4.B – Brest Auditorium
PD-L1 Expression on Immune Cells by SP142 Co-LocalisesWith Dendritic Cells and is Associated With Improved Overall Survival with Atezolizumab in Patients With Untreated Metastatic Urothelial Cancer (mUC)
Grande E, Galsky MD, Van Elzen R, Banchereau R, Peterson M, Sedano C, Koeppen H, Li H, Bamias A, Arranz JA, Kikuchi E, De Santis M, Davis ID, Mellman I, Oh S, Williams P, Bernhard S, Lee C, Kockx M, Mariathasan S

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar
03:10 PM
Duration 5mins 7.2.E - Évry Auditorium
Giredestrant (GDC-9545) vs physician choice of endocrine monotherapy (PCET) in patients (pts) with ER+, HER2– locally advanced/metastatic breast cancer (LA/mBC): Primary analysis of the phase 2, randomised, open-label acelERA BC study
Martin M, Lim E, Chavez-MacGregor M, Bardia A, Wu J, Zhang Q, Nowecki Z, Cruz F, Safin R, Kim S, Schem C, Montero A, Khan S, Bandyopadhyay R, Shivhare M, Patre M, Martinalbo J, Roncoroni L, Perez-Moreno P, Sohn J

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar
04:50 PM
Duration 10mins 7.3.O - Orléans Auditorium
MyPathway: A multiple target, multiple basket study of targeted treatments in tissue-agnostic cohorts of patients (pts) with advanced solid tumors
Swanton C, Friedman CF, Spigel DR, Bose R, Burris HA, Levy J, Wang Y, Malato J, Price R, Darbonne W, Szado T, Schulze K, Sweeney CJ, Hainsworth J, Meric-Bernstam F, Kurzrock R

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar
05:20 PM
Duration 5mins 7.3.T - Toulouse Auditorium
Phase Ia study to evaluate GDC-6036 monotherapy in patients with solid tumors with a KRAS G12C mutation
Manish R. Patel, Jong Seok Lee, Maria De Miguel, Timothy Burns, Alejandro Falcon, Tae Won Kim, Matthew G. Krebs, Hans Prenen, Einat Shacham-Shmueli, Jayesh Desai, Patricia LoRusso, Adrian Sacher, Yoonha Choi, Neekesh V. Dharia, Mark T. Lin, Sandhya Mandlekar, Stephanie Royer-Joo, Jennifer L. Schutzman, Elena Garralda

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar
05:40 PM
Duration 10mins 6.P - Paris Auditorium
IPSOS: Results from a Phase 3 study of first-line (1L) atezolizumab (atezo) vs single-agent chemotherapy (chemo) in patients (pts) with NSCLC not eligible for a platinum-containing regimen
Lee SM, Califano R, Cappuzzo F, Cortinovis D, Han B, Kumar P, Le AT, Liu G, Reck M, Reyes Contreras J, Rittmeyer A, Szczesna A, Vicente Baz D, Hu Youyou, Morris S, Hoglander E, Connors M, Vollan HK, Schulz C, Peters S

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar